The Authors describe their experience in treating 81 patients, suffering from urothelial cell carcinoma, with neo-adjuvant, adjuvant or final MVEC chemotherapy according to stage and localisation. The prospective results would seem to indicate conservative surgery and adjuvant chemotherapy for pT3N0M0G1-2 bladder tumours, prognostic improvement, at least with regard to disease-free period, in pT3N0M0 cancer, the possibility of downstaging in T4N + M + cancer and more clinical remissions in transitional cell carcinoma in the upper urinary tract. Furthermore, the therapy proved to be relatively easy for the “non-oncologist” urologists. Side effects are mentioned.
PiediferroG., EspositoC., LeonettiP.: a) “Chemioterapia sistemica MVEC: effetti collaterali”; b) “Chemioterapia sistemica MVEC: effetti preliminari”. Abstract book “Controversie nel trattamento multidisciplinare dei tumori urologici”. 1° Congresso S.I.UR.O., Santa Margherita Ligure, 25-27 novembre 1991.
2.
StokleM., MeyenburgW., WellekS., VogesG., GertenbachU., ThuroffJ.W., HuberC., HohenfellnerR.: Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J. Urol., 148: 302–307, 1992.
